DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher

Information source: Ahn-Gook Pharmaceuticals Co.,Ltd
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cough

Intervention: AG1321001(drug) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Ahn-Gook Pharmaceuticals Co.,Ltd

Official(s) and/or principal investigator(s):
Young-hwan Kim, MD, PhD, Study Chair, Affiliation: Seoul National University Hospital, Seoul, 110-744, Korea, Republic of
Choon-Taek Lee, MD, PhD, Principal Investigator, Affiliation: Seoul National University Bundang Hospital, Sungnam, Korea, Republic of
Hee-Soon Chung, MD, PhD, Principal Investigator, Affiliation: Seoul National University Boramae Hospital, Seoul, 156-707, Korea, Republic of
Ki-suk Jung, MD, PhD, Principal Investigator, Affiliation: Hallym University Sacred Heart Hospital, Anyang, Kyunggi, 430-070, Korea, Republic of
Joon Chang, MD, PhD, Principal Investigator, Affiliation: Severance Hospital, Seoul, 120-752, Korea, Republic of
Chul-min Ahn, MD, PhD, Principal Investigator, Affiliation: Yongdong Sevenrance Hospital, Seoul, 135-720, Korea, Republic of

Summary

This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.

Clinical Details

Official title: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Cough severity, Cough specific Quality of Life

Secondary outcome: Daily cough symptom, Cough frequency

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Adult between the ages of 18 and 70. 2. Patient who has cough symptom caused by following diseases: chronic bronchitis, bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis. 3. Patient requiring internal treatment due to cough symptom, who has coughing more than 3 weeks. 4. patient who will continue to cough more than 1 week.(by physician's judgment) 5. Patient who decided to participate in this clinical trial at his(her) own will and agreed in written letter of consent. 6. Patient who is trustworthy, ready for cooperation and observing the restrictions during the trial period. Exclusion Criteria: 1. Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as Acute infectious Pulmonary Disease, Tuberculosis. 2. Patient who has clinical history of sensitivity to Xanthine drug. 3. Patient who has Peptic Ulcer or Asthma (Except Cicatrix) 4. Patient whose liver or kidney function is seriously abnormal: Including the cases of sGOT, sGPT, bilirubin and blood creatinine value exceeding twice of their upper normal limit. 5. Patient whose heart function is abnormal: including the case of showing abnormal EKG test value that is clinically significant. 6. Patient who has experience to have participated in other clinical trial within two months before starting the trial. 7. Pregnant woman, lactating woman. 8. patient who has convulsion or alcoholism. 9. patient who take medicines which can not use combination with AG1321001.

Locations and Contacts

Seoul National University Hospital, Seoul 82, Korea, Republic of
Additional Information

Starting date: March 2006
Last updated: June 30, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017